Pixelgen Technologies Secures €13.26 Million Series B to Advance Spatial Mapping of Cell Surface Proteins
核心洞察
Pixelgen Technologies (搜索) closed an oversubscribed €13.26 million ($15.5 million) Series B round led by new investor Flat Capital (搜索), with continued participation from Industrifonden (搜索) and Navigare Ventures (搜索).
The Stockholm-based company's Proxiome Kit, powered by the patented Proximity Network Assay, enables high-throughput mapping of protein spatial organization on single cells at nanoscale resolution.
The new capital will fund continued technology development and global commercial expansion, with applications across immunology, haematology, oncology, and cell therapy.
Pixelgen Technologies (搜索), a Stockholm-based life sciences company, has closed an oversubscribed €13.26 million ($15.5 million) Series B funding round led by new investor Flat Capital (搜索), with continued participation from existing investors Industrifonden (搜索) and Navigare Ventures (搜索). The financing will support continued technology development and global commercial expansion of the company's platform for mapping the spatial organization of proteins on the surface of single cells.
Flat Capital (搜索) AB (publ) is investing approximately SEK 40 million in Pixelgen and is leading the company's Series B round of approximately SEK 150 million, together with existing and new investors. Alongside the financing, Pixelgen is adding Flat Capital CEO Rickard El Tarzi and life sciences veteran Ramon Felciano, Ph.D., to its board of directors.
"This financing gives us the resources to expand globally as demand grows for our Proxiome Kit and our data analysis and visualisation software. We're proud to have Flat Capital (搜索) join us and to have the continued confidence of Navigare and Industrifonden (搜索). Their support will help accelerate our commercial reach, grow our team and product portfolio, and bring molecular cell architecture to more researchers and new applications," said Pixelgen CEO and co-founder Simon Fredriksson, PhD.
A Novel Approach to Cellular Architecture
Pixelgen's technology enables researchers to study the spatial organization of proteins — the molecular machinery required to carry out cellular functions — in a new way, in which many proteins can be studied simultaneously, across many cells, and at high resolution. The company states that its Proxiome Kit is the first platform to enable high-throughput mapping of molecular cell architecture at nanoscale resolution.
While conventional proteomic approaches primarily measure protein abundance, the Proxiome Kit reveals how proteins are organized, clustered, and localized on the surface of individual cells. Powered by the patented Proximity Network Assay, the kit enables high-dimensional analysis of cell surface architecture in single cells, helping researchers move beyond abundance measurements to capture the architectural features of cell state, disease, and treatment response.
Company Origins and Commercial Trajectory
Pixelgen was founded in 2020 in Stockholm by Simon Fredriksson, Alvaro Martinez Barrio, Ph.D., Fredrik Dahl, Ph.D., and Filip Karlsson. The company is led by CEO and co-founder Simon Fredriksson, previously a co-founder of Olink AB (搜索). Pixelgen emerged from stealth in December 2022 following the close of an approximate €5.13 million ($6 million) Seed round led by Navigare Ventures (搜索).
The technology was described in Nature Methods in 2024, and the patented Proximity Network Assay was commercialized in the spring of 2025 as the Pixelgen Proxiome Kit. The company's customers include leading academic institutions and pharmaceutical companies, primarily in Europe and North America.
Clinical and Therapeutic Potential
The company's platform has applications across immunology, haematology, oncology, and cell therapy. Rickard El Tarzi, CEO of Flat Capital (搜索), highlighted the technology's broader significance: "Pixelgen has the potential to become the next Swedish success story in life science. Over the past few years, the team has invested in developing a unique technology that gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way. In time, this could contribute to the development of new and better therapies in areas such as cancer, immunology and autoimmune diseases."
El Tarzi added: "Pixelgen's technology gives researchers the ability to study disease mechanisms and identify novel biomarkers in an entirely new way. We believe this could open new avenues for research in cancer, immunology and autoimmune disease, while broadening our understanding of basic biology."
Simon Fredriksson emphasized the market response since launch: "In the short time since our launch last year, we have seen how Pixelgen's technology is changing the way our customers do their research. We are seeing strong demand in a large global market, and with new capital we will be able to convert that into strong growth."
The company plans to use the capital to accelerate global commercialization of its Proxiome Kit and expand its presence in key markets.